These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26755491)

  • 21. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
    Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
    BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and toxicity of an accelerated hypofractionated radiation therapy protocol in cats with oral squamous cell carcinoma.
    Poirier VJ; Kaser-Hotz B; Vail DM; Straw RC
    Vet Radiol Ultrasound; 2013; 54(1):81-8. PubMed ID: 23078236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial-mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro.
    Altamura G; Martano M; Matrone A; Corteggio A; Borzacchiello G
    Vet Comp Oncol; 2024 Mar; 22(1):149-155. PubMed ID: 38030131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.
    Cannon CM; Trembley JH; Kren BT; Unger GM; O'Sullivan MG; Cornax I; Modiano JF; Ahmed K
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):80-86. PubMed ID: 28335614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A nine-day accelerated radiation protocol for feline squamous cell carcinoma.
    Fidel JL; Sellon RK; Houston RK; Wheeler BA
    Vet Radiol Ultrasound; 2007; 48(5):482-5. PubMed ID: 17899987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
    Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
    J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
    Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
    Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate.
    Dedeaux AM; Langohr IM; Boudreaux BB
    Can Vet J; 2018 Jul; 59(7):751-754. PubMed ID: 30026621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Wouda RM; Hocker SE; Higginbotham ML
    Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate.
    Alonso-Miguel D; Valdivia G; García-San José P; Alonso-Diez Á; Clares I; Portero M; Peña L; Pérez-Alenza MD
    Vet Comp Oncol; 2022 Mar; 20(1):179-188. PubMed ID: 34390295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
    London CA; Gardner HL; Mathie T; Stingle N; Portela R; Pennell ML; Clifford CA; Rosenberg MP; Vail DM; Williams LE; Cronin KL; Wilson-Robles H; Borgatti A; Henry CJ; Bailey DB; Locke J; Northrup NC; Crawford-Jakubiak M; Gill VL; Klein MK; Ruslander DM; Thamm DH; Phillips B; Post G
    PLoS One; 2015; 10(4):e0124889. PubMed ID: 25923466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
    Rossi F; Sabattini S; Vascellari M; Marconato L
    Vet Comp Oncol; 2018 Dec; 16(4):497-504. PubMed ID: 29806156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma.
    Evans SM; LaCreta F; Helfand S; VanWinkle T; Curran WJ; Brown DQ; Hanks G
    Int J Radiat Oncol Biol Phys; 1991 Apr; 20(4):703-8. PubMed ID: 1825993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response of feline oral squamous cell carcinoma to palliative radiation therapy.
    Bregazzi VS; LaRue SM; Powers BE; Fettman MJ; Ogilvie GK; Withrow SJ
    Vet Radiol Ultrasound; 2001; 42(1):77-9. PubMed ID: 11245242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.
    de Vos J; Ramos Vega S; Noorman E; de Vos P
    Vet Comp Oncol; 2012 Sep; 10(3):206-13. PubMed ID: 22236048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyamine inhibitors for treatment of feline oral squamous cell carcinoma: a proof-of-concept study.
    Lewis JR; O'Brien TG; Skorupski KA; Krick EL; Reiter AM; Jennings MW; Jurney CH; Shofer FS
    J Vet Dent; 2013; 30(3):140-5. PubMed ID: 24371920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
    Heaton CM; Fernandes AFA; Jark PC; Pan X
    J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia.
    Alonso-Miguel D; García-San José P; González Sanz S; Clarés Moral I; Pérez-Alenza MD
    N Z Vet J; 2021 Jul; 69(4):234-239. PubMed ID: 33944682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computed tomographic features of oral squamous cell carcinoma in cats: 18 cases (2002-2008).
    Gendler A; Lewis JR; Reetz JA; Schwarz T
    J Am Vet Med Assoc; 2010 Feb; 236(3):319-25. PubMed ID: 20113245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.